Precigen (PGEN) Director Buys 15,000 Shares at $4.60

Nancy H. Agee, a director of Precigen, Inc. (PGEN), reported purchasing 15,000 shares of the company's common stock on 09/04/2025 at a price of $4.60 per share.

Rhea-AI Filing Summary

Nancy H. Agee, a director of Precigen, Inc. (PGEN), reported purchasing 15,000 shares of the company's common stock on 09/04/2025 at a price of $4.60 per share. After the purchase she beneficially owns 217,841 shares, held directly. The filing shows no derivative transactions and was signed on 09/05/2025 by Nancy H. Agee via attorney-in-fact.

Positive

• Director purchase disclosed: Nancy H. Agee acquired 15,000 common shares, indicating insider buying activity.
• Increased direct ownership: Beneficial ownership rose to 217,841 shares following the transaction.
• Clean disclosure: No derivatives reported and the Form 4 was timely signed, meeting Section 16 reporting requirements.

Negative

• None.

Insights

Securities Analyst

TL;DR: A director executed an open-market purchase of common stock, modestly increasing direct ownership.

The Form 4 documents a straightforward non-derivative purchase: 15,000 shares at $4.60 each, raising direct beneficial ownership to 217,841 shares. This is a routine insider buy disclosed under Section 16 and does not include options, warrants, or other derivative instruments. The size of the purchase relative to total outstanding shares is not provided in the filing, so materiality to valuation cannot be determined from this document alone.

Corporate Governance Expert

TL;DR: Insider purchase by a director is a governance signal but lacks context on size and intent.

The filing confirms the transaction was reported promptly and executed directly, which aligns with disclosure obligations. There is no indication of Rule 10b5-1 plan or other arrangements disclosed on the form. Without information on the director's historical trading pattern or the company's share count, implications for control or voting power cannot be assessed from this filing alone.

Insider Trade Summary

Net Buyer: 15,000 shares

Net Buy 1 txn

Insider AGEE NANCY H

Role Director

Bought 15,000 shs ($69K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	15,000	$4.60	$69K

Holdings After Transaction: Common Stock — 217,841 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nancy H. Agee report on the Form 4 for PGEN?

The Form 4 reports a purchase of 15,000 shares of Precigen common stock on 09/04/2025 at $4.60 per share.

How many PGEN shares does Nancy H. Agee beneficially own after the transaction?

The filing shows she beneficially owns 217,841 shares following the reported purchase.

Were any derivative securities reported on this Form 4 for PGEN?

No. The Form 4 discloses only a non-derivative common stock purchase and contains no derivative transactions.

When was the Form 4 for this transaction signed?

The signature block shows the form was signed on 09/05/2025 by Nancy H. Agee via attorney-in-fact.

Does the filing state the purchase was made under a 10b5-1 plan?

The form does not indicate that the transaction was made pursuant to a 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/05/2025 - 05:46 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AGEE NANCY H

(Last) (First) (Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN MD 20876

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2025		P		15,000	A	$4.6	217,841	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Nancy H. Agee, by Donald P. Lehr, as attorney-in-fact	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.